Results from this study demonstrate a reduction in the proportion of patients requiring COPD/chronic bronchitis related readmission within 30 days and 12 months of the Aerobika® OPEP device therapy initiation compared to an alternative OPEP device.
This further supports the use of the Aerobika® OPEP device as an add-on to usual care to manage COPD/chronic bronchitis patients post-exacerbation and highlights that not all OPEP devices are the same in terms of 30-day and 12-month readmissions
The continuous involvement of patients resulted in a number of key insights that helped guide the design process, resulting in the development of a chamber that patients are much more likely to use while on-the-go.
COPD is a chronic and progressive disease that requires regular self-administration of inhaled medications. However, as the disease progresses, reduced respiratory muscle strength may prevent patients from generating sufficient inspiratory effort to effectively use dry-powder inhalers (DPIs) [1, 2]. In contrast, patients can inhale slowly or breathe tidally from a pMDI with VHC without the need to coordinate with inhaler actuation [3].
As a medical device manufacturer, we are committed to minimizing any disruption to the supply of our products to our customers globally, during this unprecedented time with the outbreak of COVID-19.
The DPI results suggest that inhalation breathing profiles can have an appreciable impact upon aerosol delivery, with one participant having much less predicted medication as fine particles
In contrast, although the inhalation profiles across all participants were also divergent when asked to inhale from the pMDI + VHC, either tidal breathing or by a slow, deep inhalation, all volunteers would have received a relatively consistent amount of medication.
It also appears that the pMDI + VHC platform delivers a larger FPM<5.0 µm for both APIs and a consequently smaller coarse particle mass. However, it is recognized that more investigation is warranted with a larger number of volunteers and with other passive DPIs having different resistances
The prototype AeroChamber2go* spacer device was preferred by patients compared to the A2A† spacer and provides a good option for patients currently using the Metered Dose Inhaler without a spacer while on-the-go.
The delivery of medication from the AEROECLIPSE* II BAN* to the lungs was not affected by the incorporation of the Aerobika* OPEP device. Aerosol deposition within the lung was unaltered by the addition of the OPEP device as evidenced by the near identical percentage of the dose being deposited in both the peripheral and central airways.
BAN+OPEP therapy could offer the clinician the opportunity for combined treatment thereby reducing the time needed for the patient to take both nebulizer and OPEP treatments separately.
Evaluations of inhaler use have demonstrated that mishandling of MDIs is commonplace.
One of the most common errors is the failure to coordinate inhalation with actuation of the inhaler
One of the reasons why VHCs are often prescribed, is to reduce the severity of this error
This Functional Respiratory Imaging (FRI) based study assessed the likely severity of a short inhalation delay (from actuation) with an MDI alone and how it contrasted to the use with a VHC
While it’s one of the most anticipated seasons of the year, summer can also be the most difficult season for Canadians living with COPD (chronic obstructive pulmonary disease). We want to help you make the most of it! Here’s what you need to know about summer, and how you can enjoy yours this year.
Asthma impacts different people in different ways. Most people are able to control their asthma with regular use of their controller medication and using their reliever medication when necessary. However, for many it can be difficult to recognize when their asthma is not controlled. When asthma is well-controlled, you will experience little to no asthma symptoms.
It is our pleasure to announce that in honour of the late Mitchell Baran, the founder and leader of the Trudell Medical Group of Companies, the City of London has renamed the portion of Third Street that two of the Trudell Companies are located to “Baransway Drive”.
This article describes the generative, patient-centered, design process used in the development of a prototype VHC intended primarily for use ‘on the go’ by adults with persistent asthma or newly diagnosed COPD.
Presented at the British Thoracic Society December 2018.
Having a child with asthma can be stressful for parents, especially for financially strapped ones struggling to pay for an arsenal of puffers and pills for their child’s treatment. Because of this, those healthcare professionals who recommend spacer chambers may suggest one of many lower-cost versions that are available on the market today. But focusing only on cost may be putting a child’s health at risk.
If you suffer from Chronic Obstructive Lung Disease (COPD), simple tasks can start to feel larger than life. While there is no cure, there are steps you can take to improve your health and quality of life.
Living a full life with Chronic Obstructive Pulmonary Disease (COPD) is more accessible than ever before with today’s online resources. Whether you’re looking for in-depth tutorials, facts, or simple tips on self-management, the web offers information at your fingertips. Here’s a few of our favourite bookmark-worthy websites for you!
While the hot summer months may affect the everyday management of your lung health, it doesn’t have to keep you from living your fullest life. Here are a few tips to help you find the breathing spaces you need this summer.
Post-operative pulmonary complications (PPCs) are a major burden to the healthcare system. A new real-world study published in Pulmonary Therapy, indicates significant reductions in costs when using the AEROBIKA*oscillating positive expiratory pressure (OPEP) device in the postoperative care setting.1
May 1, 2018: Today is the 20th annual World Asthma Day, an event held each May to raise awareness of Asthma worldwide. World Asthma Day is organized by the Global Initiative for Asthma, or GINA (www.ginasthma.org), a World Health Organization collaborative and 501(c)3 organization founded in 1993.
Valved holding chambers are widely prescribed to assist patients receiving inhaled medications by avoiding losses caused by imperfect coordination of inhalation and actuation and also to reduce oropharyngeal deposition.
Regardless of whether using a solution based formulation (like Qvar) or a suspension formulation (Flovent), the use of a valved holding chamber reduced the amount of medication deposited in the mouth (oropharynx) and increased the potential for lung delivery
This study can be used to help demonstrate the value of using a valved holding chamber for both solution and suspension formulated metered dose inhalers and for all patient populations, including adults
